Carlo Ganini
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Carlo Ganini has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Alessandro Mauriello
Department of Experimental Medicine, TOR, University of Rome Tor Vergata, Rome, Italy
1 shared publication - Anastasios D. Asimakopoulos
Unit of Urology, Fondazione PTV Policlinico Tor Vergata, Rome, Italy
1 shared publication - Angela Cappello
Interdisciplinary Department of Medicine, University of Bari “Aldo Moro”, Bari, Italy
1 shared publication - Benedetta Imperiali
Department of Experimental Medicine, Biochemistry Lab, University of Rome Tor Vergata, Rome, Italy
1 shared publication - Camillo Porta
Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari and University of Bari "A. Moro," Bari, Italy
1 shared publication - Chiara Cipriani
Department of Experimental Medicine, University of Rome Tor Vergata, 00133 Rome, Italy
1 shared publication
Latest Publications
- Open Access
- 24 October 2026
- Published by Springer Nature in Oncogenesis
Metabolic and epigenetic reprogramming as novel vulnerabilities in renal cell carcinoma
- 24 October 2026
- Published by Springer Nature in Oncogenesis
Open AccessMetabolic and epigenetic reprogramming as novel vulnerabilities in renal cell carcinoma
- Open Access
- 30 March 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (7) , 6519
ZNF750: A Novel Prognostic Biomarker in Metastatic Prostate Cancer
Prostate cancer is the most frequently diagnosed cancer and the fifth leading cause of cancer death among men in 2020. The clinical decision making for prostate cancer patients is based on the stratification of the patients according to both clinical and pathological parameters such as Gleason score and prostate-specific antigen levels. However, these tools still do not adequately predict patient outcome. The aim of this study was to investigate whether ZNF750 could have a role in better stratifying patients, identifying those with a higher risk of metastasis and with the poorest prognosis. The data reported here revealed that ZNF750 protein levels are reduced in human prostate cancer samples, and this reduction is even higher in metastatic samples. Interestingly, nuclear positivity is significantly reduced in patients with metastatic prostate cancer, regardless of both Gleason score and grade group. More importantly, the bioinformatics analysis indicates that ZNF750 expression is positively correlated with better prognosis. Overall, our findings suggest that nuclear expression of ZNF750 may be a reliable prognostic biomarker for metastatic prostate cancer, which lays the foundation for the development of new biological therapies.
- 30 March 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (7) , 6519
Open AccessZNF750: A Novel Prognostic Biomarker in Metastatic Prostate Cancer
Prostate cancer is the most frequently diagnosed cancer and the fifth leading cause of cancer death among men in 2020. The clinical decision making for prostate cancer patients is based on the stratification of the patients according to both clinical and pathological parameters such as Gleason score and prostate-specific antigen levels. However, these tools still do not adequately predict patient outcome. The aim of this study was to investigate whether ZNF750 could have a role in better stratifying patients, identifying those with a higher risk of metastasis and with the poorest prognosis. The data reported here revealed that ZNF750 protein levels are reduced in human prostate cancer samples, and this reduction is even higher in metastatic samples. Interestingly, nuclear positivity is significantly reduced in patients with metastatic prostate cancer, regardless of both Gleason score and grade group. More importantly, the bioinformatics analysis indicates that ZNF750 expression is positively correlated with better prognosis. Overall, our findings suggest that nuclear expression of ZNF750 may be a reliable prognostic biomarker for metastatic prostate cancer, which lays the foundation for the development of new biological therapies.